Skip to main content

Drug Interactions between anagrelide and eptifibatide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

anagrelide eptifibatide

Applies to: anagrelide and eptifibatide

MONITOR CLOSELY: The combination of glycoprotein IIb/IIIa inhibitors and anagrelide can theoretically significantly increase the risk of bleeding. GP IIb/IIIa inhibitors inhibit platelet aggregation by blocking the fibrinogen, von Willebrand factor, and other adhesive ligands to platelets. The mechanism whereby anagrelide decreases platelet concentrations is not known. The combination of these drugs, therefore, could decrease platelet number and function.

MANAGEMENT: Extraordinary precautions are recommended if these drugs must be used together, including monitoring platelet counts and hemoglobin concentrations. In addition, invasive procedures, such as urinary catheterization, nasogastric or nasotracheal intubation, and even venous punctures should be avoided or minimized. Non-compressible venous access sites, such as jugular or subclavian sites, should be avoided.

References

  1. (2001) "Product Information. ReoPro (abciximab)." Lilly, Eli and Company
  2. (2001) "Product Information. Integrilin (eptifibatide)." Schering Corporation

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer